Plasmodium vivax susceptibility to ferroquine

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2228-2230

  Leimanis, M L ^a   Jaidee, A ^a   Sriprawat, K ^a   Kaewpongsri, S ^a   Suwanarusk, R ^b   Barends, M ^a   Phyo, A P ^a   Russell, B ^b   Renia, L ^b   Nosten, F ^a,c,d  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b AGENCY FOR SCIENCE   (Singapore)

^c MAHIDOL UNIVERSITY   (Thailand)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; FERROQUINE; MEFLOQUINE; PIPERAQUINE; SSR 97193; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; IC 50; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARASITE ISOLATION; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; SCHIZONT; STRUCTURE ACTIVITY RELATION;

AMINOQUINOLINES; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FERROUS COMPOUNDS; HUMANS; MALARIA, VIVAX; MICROBIAL SENSITIVITY TESTS; PLASMODIUM VIVAX; THAILAND;

EID: 77951228214     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01572-09     Document Type: Article

References (17)

1. Anstey, N. M., B. Russell, T. W. Yeo, and R. N. Price. 2009. The pathophysiology of vivax malaria. Trends Parasitol. 25:220-227.
2. Atteke, C., J. M. Ndong, A. Aubouy, L. Maciejewski, J. Brocard, J. Lebibi, and P. Deloron. 2003. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J. Antimicrob. Chemother. 51:1021-1024.
3. Baird, J. K. 2009. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 22:508-534.
4. Barends, M., A. Jaidee, N. Khaohirun, P. Singhasivanon, and F. Nosten. 2007. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar. J. 6:81.
5. Biot, C., L. Delhaes, C. M. N'Diaye, L. A. Maciejewski, D. Camus, D. Dive, and J. S. Brocard. 1999. Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds. Bioorg. Med. Chem. 7:2843-2847.
6. Daher, W., C. Biot, T. Fandeur, H. Jouin, L. Pelinski, E. Viscogliosi, L. Fraisse, B. Pradines, J. Brocard, J. Khalife, and D. Dive. 2006. Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar. J. 5:11.
7. Daher, W., L. Pelinski, S. Klieber, F. Sadoun, V. Meunier, M. Bourrie, C. Biot, F. Guillou, G. Fabre, J. Brocard, L. Fraisse, J. P. Maffrand, J. Khalife, and D. Dive. 2006. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab. Dispos. 34:667-682.
8. Druilhe, P., P. Brasseur, C. Blanc, and M. Makler. 2007. Improved assessment of Plasmodium vivax response to antimalarial drugs by a colorimetric double-site Plasmodium lactate dehydrogenase antigen capture enzymelinked immunosorbent assay. Antimicrob. Agents Chemother. 51:2112-2116.
9. Kreidenweiss, A., P. G. Kremsner, K. Dietz, and B. Mordmuller. 2006. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 75:1178-1181.
10. Lek-Uthai, U., R. Suwanarusk, R. Ruengweerayut, T. S. Skinner-Adams, F. Nosten, D. L. Gardiner, P. Boonma, K. A. Piera, K. T. Andrews, B. Machunter, J. S. McCarthy, N. M. Anstey, R. N. Price, and B. Russell. 2008. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob. Agents Chemother. 52:2435-2441.
11. Maguire, J. D., Krisin, H. Marwoto, T. L. Richie, D. J. Fryauff, and J. K. Baird. 2006. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin. Infect. Dis. 42:1067-1072.
12. Powell, R. D., and E. M. Berglund. 1974. Effects of chloroquine upon the maturation of asexual erythrocytic forms of Plasmodium vivax in vitro. Am. J. Trop. Med. Hyg. 23:1007-1014.
13. Ratcliff, A., H. Siswantoro, E. Kenangalem, M. Wuwung, A. Brockman, M. D. Edstein, F. Laihad, E. P. Ebsworth, N. M. Anstey, E. Tjitra, and R. N. Price. 2007. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 101:351-359.
14. Russell, B., F. Chalfein, B. Prasetyorini, E. Kenangalem, K. Piera, R. Suwanarusk, A. Brockman, P. Prayoga, P. Sugiarto, Q. Cheng, E. Tjitra, N. M. Anstey, and R. N. Price. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045.
15. Russell, B. M., R. Udomsangpetch, K. H. Rieckmann, B. M. Kotecka, R. E. Coleman, and J. Sattabongkot. 2003. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47:170-173.
16. Sharrock, W. W., R. Suwanarusk, U. Lek-Uthai, M. D. Edstein, V. Kosaisavee, T. Travers, A. Jaidee, K. Sriprawat, R. N. Price, F. Nosten, and B. Russell. 2008. Plasmodium vivax trophozoites insensitive to chloroquine. Malar. J. 7:94.
17. Sriprawat, K., S. Kaewpongsri, R. Suwanarusk, M. L. Leimanis, U. Lek-Uthai, A. P. Phyo, G. Snounou, B. Russell, L. Renia, and F. Nosten. 2009. Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood. Malar. J. 8:115.